scholarly journals Diode laser as local treatment for oral Kaposi's sarcoma in HIV young patient: a case report

2021 ◽  
Vol 27 (2) ◽  
pp. 31
Author(s):  
Niccolò Lombardi ◽  
Elena Varoni ◽  
Laura Moneghini ◽  
Giovanni Lodi
Keyword(s):  
Diode Laser ◽  
Highly Active Antiretroviral Therapy ◽  
Kaposi's Sarcoma ◽  
Treatment Options ◽  
Local Treatment ◽  
Human Herpesvirus ◽  
Invasive Procedure ◽  
Kaposi’S Sarcoma ◽  
Surgical Excision ◽  
Highly Active

Introduction: Kaposi's sarcoma (KS) is a malignant mucocutaneous neoplasm caused by human herpesvirus 8 (HHV-8). Four types of KS exist and, in each of them, the patient could develop skin and visceral lesions. Surgical excision, radiotherapy, intralesional chemotherapy and systemic chemotherapy are widely accepted as treatment options. Observation: The aim of this paper is to present diode laser as minimally invasive procedure in management of oral KS. We report here a case of multiple oral lesions of acquired immunodeficiency syndrome (AIDS)-associated KS, which has been solely treated with diode laser. Discussion: There is no bibliography on local treatment of oral KS with diode laser and this clinical case appears to be the first regarding this technique. Conclusion: This conservative approach, in association with highly active antiretroviral therapy (HAART), is safe and effective, shows fewer side effects than chemotherapy, radiotherapy and surgical excision and may be evaluated as potential treatment for oral KS.

Kaposi's sarcoma associated with highly active antiretroviral therapy

2005 ◽  
Vol 16 (8) ◽  
pp. 583-583
Author(s):  
Heidi M Crane ◽  
Heike Deubner ◽  
Jane C Huang ◽  
Paul E Swanson ◽  
Robert D Harrington
Keyword(s):  
Antiretroviral Therapy ◽  
Highly Active Antiretroviral Therapy ◽  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma ◽  
Highly Active

scholarly journals Phase II Study of Bevacizumab in Patients With HIV-Associated Kaposi's Sarcoma Receiving Antiretroviral Therapy

2012 ◽  
Vol 30 (13) ◽  
pp. 1476-1483 ◽  
Author(s):  
Thomas S. Uldrick ◽  
Kathleen M. Wyvill ◽  
Pallavi Kumar ◽  
Deirdre O'Mahony ◽  
Wendy Bernstein ◽  
...  
Keyword(s):  
Antiretroviral Therapy ◽  
Highly Active Antiretroviral Therapy ◽  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma ◽  
Complete Response ◽  
Median Number ◽  
Primary Objective ◽  
Cytotoxic Agents ◽  
Prior Chemotherapy ◽  
Highly Active

Purpose Alternatives to cytotoxic agents are desirable for patients with HIV-associated Kaposi's sarcoma (KS). Vascular endothelial growth factor-A (VEGF-A) contributes to KS pathogenesis. We evaluated the humanized anti–VEGF-A monoclonal antibody, bevacizumab, in patients with HIV-KS. Patients and Methods Patients with HIV-KS who either experienced progression while receiving highly active antiretroviral therapy (HAART) for at least 1 month or did not regress despite HAART for at least 4 months were administered bevacizumab 15 mg/kg intravenously on days 1 and 8 and then every 3 weeks. The primary objective was assessment of antitumor activity using modified AIDS Clinical Trial Group (ACTG) criteria for HIV-KS. HIV-uninfected patients were also eligible and observed separately. Results Seventeen HIV-infected patients were enrolled. Fourteen patients had been receiving effective HAART for at least 6 months (median, 1 year). Thirteen patients had advanced disease (ACTG T1), 13 patients had received prior chemotherapy for KS, and seven patients had CD4 count less than 200 cells/μL. Median number of cycles was 10 (range, 1 to 37 cycles); median follow-up was 8.3 months (range, 3 to 36 months). Of 16 assessable patients, best tumor responses observed were complete response (CR) in three patients (19%), partial response (PR) in two patients (12%), stable disease in nine patients (56%), and progressive disease in two patients (12%). Overall response rate (CR + PR) was 31% (95% CI, 11% to 58.7%). Four of five responders had received prior chemotherapy for KS. Over 202 cycles, grade 3 to 4 adverse events at least possibly attributed to therapy included hypertension (n = 7), neutropenia (n = 5), cellulitis (n = 3), and headache (n = 2). Conclusion Bevacizumab is tolerated in patients with HIV-KS and has activity in a subset of patients.

scholarly journals Lymphadenopathy after initiating HAART in an HIV-positive patient with Kaposi's sarcoma: A case of multicentric Castleman's disease

2015 ◽  
Vol 2 (LATEST ONLINE) ◽  
Author(s):  
Daniel Micallef ◽  
Jason Attard ◽  
Charles Mallia Azzopardi ◽  
Michael John Boffa
Keyword(s):  
Highly Active Antiretroviral Therapy ◽  
Immune Reconstitution ◽  
Kaposi's Sarcoma ◽  
Castleman’S Disease ◽  
Kaposi’S Sarcoma ◽  
Rapid Progression ◽  
Castleman's Disease ◽  
Suspected Sepsis ◽  
Highly Active ◽  
Life Saving

We present the case of a 33-year-old lady who was diagnosed with disseminated Kaposi’s sarcoma and HIV infection. The patient improved on highly active antiretroviral therapy (HAART), however, nine days into treatment, she became febrile and dyspnoeic and developed tender cervical and axillary lymphadenopathy. Despite treatment for suspected sepsis and immune reconstitution, she died in intensive care. Lymph node biopsies revealed coexistent Castleman’s disease and Kaposi’s sarcoma. Initiation of HAART can be rarely associated with unmasking and rapid progression of Castleman’s disease, a phenomenon called immune reconstitution. Urgent investigation and treatment with agents such as steroids and cytotoxic drugs can be life-saving.

The influence of highly active antiretroviral therapy on AIDS-associated Kaposi's sarcoma

1999 ◽  
Vol 140 (5) ◽  
pp. 875-881 ◽  
Author(s):  
N Dupin ◽  
V Rubin De Cervens ◽  
I Gorin ◽  
V Calvez ◽  
E Pessis ◽  
...  
Keyword(s):  
Antiretroviral Therapy ◽  
Highly Active Antiretroviral Therapy ◽  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma ◽  
Highly Active
Sign in / Sign up

Export Citation Format

Share Document